PATENT CLAIM ANALYSIS

Application Number: 16175895
Application Type: Utility
Filing Date: 2018-10
Publication Date: 2019-05
Patent Classification: ["514", "318000"]

Abstract:
The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically acceptable salts or solvates thereof, wherein all the variables are as defined herein. These compounds modulate the activity of farnesoid X receptor (FXR), for example, as agonists. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating a disease, disorder, or condition associated with FXR dysregulation, such as pathological fibrosis, transplant rejection, cancer, osteoporosis, and inflammatory disorders, by using the compounds and pharmaceutical compositions.

Claim (Index 13):
A method of treating a disease or disorder, comprising administering to a mammalian patent a compound according to  claim 1  or a pharmaceutically acceptable salt thereof, wherein said disease or disorder is pathological fibrosis, cancer, inflammatory disorders, metabolic, or cholestatic disorders.

Metadata:
- Claim Count in Document: 5.0
- Percentile: 97.0
- Lexical Diversity: 1.5
- Patent Class: 514.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['14971875', '15541018', '14971825', '16322945', '12377307']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7855939908266483
- 35 USC 102 Novelty (BERT): 0.5349008745278458
- Combined Prediction Score: 0.760524679196768
- Mean Citation Score: 329.48176399999994
- Max Citation Score: 338.1815
- Similarity Product: 217.13405748853089

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test